Sands Capital Management
RARE icon

Sands Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Sands Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67.3M Sell
3,214,533
-271,191
-8% -$6.11M 0.26% 46
2025
Q4 		$80.2M Sell
3,485,724
-284,129
-8% -$9.34M 0.24% 48
2025
Q3 		$113M Sell
3,769,853
-173,632
-4% -$5.21M 0.31% 49
2025
Q2 		$143M Sell
3,943,485
-220,076
-5% -$7.93M 0.41% 42
2025
Q1 		$151M Sell
4,163,561
-134,442
-3% -$5.59M 0.51% 39
2024
Q4 		$181M Sell
4,298,003
-820,252
-16% -$40.7M 0.54% 39
2024
Q3 		$284M Sell
5,118,255
-236,495
-4% -$12M 0.86% 34
2024
Q2 		$220M Buy
5,354,750
+1,495,303
+39% +$63.8M 0.65% 37
2024
Q1 		$180M Sell
3,859,447
-258,561
-6% -$12.2M 0.5% 41
2023
Q4 		$197M Buy
4,118,008
+1,540,791
+60% +$59.7M 0.6% 40
2023
Q3 		$91.9M Sell
2,577,217
-96,421
-4% -$3.82M 0.31% 46
2023
Q2 		$123M Buy
+2,673,638
New +$124M 0.38% 46

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sands Capital Management's RARE Position: Q1 2026 in Review

Sands Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 7.8% in Q1 2026, selling an estimated $6.11M and leaving 3,214,533 shares worth $67.3M. The position accounts for 0.26% of the portfolio, ranked #46.

Sands Capital Management first reported a position in RARE in Q2 2023 and has held it in 12 quarters since. The position peaked at $284M in Q3 2024. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Sands Capital Management held 3,214,533 shares of Ultragenyx Pharmaceutical worth $67.3M as of Q1 2026.
  • Sands Capital Management sold 271,191 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $6.11M.
  • Ultragenyx Pharmaceutical made up 0.26% of Sands Capital Management's portfolio in Q1 2026, its #46 holding.
  • Sands Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and has held it in 12 quarters since.
  • Sands Capital Management's Ultragenyx Pharmaceutical position peaked at $284M in Q3 2024.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Sands Capital Management's 13F filing for Q1 2026, filed 8 May 2026.